Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association.

Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association.:

Related Articles

Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association.

Expert Opin Ther Pat. 2020 Feb 01;:

Authors: Quintella CM, Quintella HM, Rohweder M, Quintella GM

Abstract

Introduction: This review aims to assess the available technologies, advances and trends from technological readiness level 4 to level 8 for cancer immunologic therapeutics using the association of OX40 and CPG-ODN, usually known as cancer vaccine.Areas covered: Patent documents and clinic studies referring the use of CpG-ODN and of OX40 association for cancer therapeutics. Patent data was obtained within the worldwide basis of the European Patent Office (EPO). The 138 patents of 36 patent families found were analyzed focusing on word distribution of technology developers and potential markets, legal status, annual evolution of first priority, technological domains, applicants and co-applicants and detailed analysis of each technology. Two clinical studies are in progress.Expert opinion: Traditional methods post cancer diagnosis are being replaced by immunological association therapies. It is expected that the development of cancer vaccines will expand the scope of cancer-specific immunotherapy, especially if associated with alternative systems for expression and delivery with future potential. It is expected that genetic and controlled and/or specific nano delivery are improved. Furthermore, these new developments will likely address the problem of long-term treatments, reducing the cancer mortality and reducing the patient numbers worldwide.

PMID: 32008403 [PubMed - as supplied by publisher]